Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Event Logistics

- PMLiVE

infill healthcare communication rebrands and appoints UK head

Mark Watson takes on the newly-created role of director, infill UK

The doctor will see you now?

Access to healthcare and European variation

The art of changing behaviour with virtual technology

In April’s issue of PME, Ella Nuttall (Health Psychology Specialist at Lucid Group) explains how changing behaviour requires a combination of science and art. She outlines how the impact of...

Lucid Group Communications Limited

- PMLiVE

Blue Latitude Health hires 7 new members of staff in 2016 Q1

Blue Latitude Health has added seven new full time members of staff in the first quarter of 2016.

Blue Latitude Health

- PMLiVE

Client relationships in the ever-changing marketing landscape

Client Lead Ben Routley talks about what Blue Latitude Health do to set ourselves apart, and what our secret to building long-lasting client relationships is.

Blue Latitude Health

- PMLiVE

FDA panel says no to quick approval of Clovis’ rociletinib

Recommends waiting for phase III trial results after "serious" safety concerns

Sanofi reception

Sanofi takeover bid rebuffed by Medivation

Had sought to boost its portfolio by acquiring the US cancer therapies firm

- PMLiVE

An apple a day?

Can lives be saved by eating fruit and vegetables?

Dr Michael Watson appointed as president of Valera

Former Sanofi Pasteur policy head joins Moderna Therapeutics firm

- PMLiVE

Eagle Genomics appoints executive chairman

Anthony Finbow replaces Alan Barrell

- PMLiVE

Lucid CEO discusses the importance of company culture

In April’s Smart Thinking blog on pmlive.com, Dennis O’Brien (Lucid CEO) discusses company culture and how individual contribution is everything.Dennis explains that, despite organisations being obsessed with meeting financial targets every...

Lucid Group Communications Limited

- PMLiVE

AbbVie and Roche to launch Venclexta within a week

FDA approves first-in-class BCL-2 inhibitor to treat chronic lymphocytic leukaemia patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links